

Appendix 1: References

1. May M, Gompels M, Delpech V, et al. Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study. *BMJ* 2011;343:d6106.
2. Wood E, Kerr T, Marshall B, et al. Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study. *BMJ* 2009;338:b1649.
3. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. *N Engl J Med* 2011;365:493-505.
4. Althoff KN, Gange SJ, Klein MB, et al. Late presentation for human immunodeficiency virus care in the United States and Canada. *Clin Infect Dis* 2010;50:1512-20.
5. Samson L, King S. Evidence-based guidelines for universal counselling and offering of HIV testing in pregnancy in Canada. *CMAJ* 1998;158:1449-57.
6. Branson BM, Handsfield HH, Lampe MA, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. *MMWR Recomm Rep* 2006;55(RR-14):1-17.
7. National Institute for Health and Clinical Excellence. *NICE calls for routine offer of HIV tests in high prevalence areas*. London (UK): the Institute; 2011. Available: www.nice.org.uk/newsroom/news/NICECallsForRoutineOfferOfHIVTestsInHighPrevalenceAreas.jsp (accessed 2012 Oct. 7).
8. Yazdanpanah Y, Sloan CE, Charlois-Ou C, et al. Routine HIV screening in France: clinical impact and cost-effectiveness. *PLoS ONE* 2010;5:e13132.
9. Sanders GD, Bayoumi AM, Sundaram V, et al. Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. *N Engl J Med* 2005;352:570-85.
10. Montaner JS, Lima VD, Barrios R, et al. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. *Lancet* 2010;376:532-9.